Key clinical point: A review of SEER data suggests black race, polypharmacy, and increasing age were associated with poor adherence to lenalidomide in older patients with newly diagnosed multiple myeloma.
Major finding: Among patients in the analysis, black race (adjusted odds ratio [aOR], 1.72), polypharmacy (aOR per drug, 1.04), and increasing age (aOR per year, 1.03) were significantly associated with poor adherence.
Study details: A SEER database analysis of 793 older patients with multiple myeloma.
Disclosures: The National Institutes of Health funded the study. No conflicts of interest were reported.
Mian H et al. Clin Lymphoma Myeloma Leuk. 2019 Oct 9. doi: 10.1016/j.clml.2019.09.618.